 Mario Enrico Canonico
Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 10 | 2026 | 509 | 3.170 |
Why?
| | Platelet Aggregation Inhibitors | 18 | 2026 | 499 | 2.820 |
Why?
| | Acute Coronary Syndrome | 10 | 2026 | 297 | 2.310 |
Why?
| | Mineralocorticoid Receptor Antagonists | 3 | 2026 | 69 | 1.960 |
Why?
| | Stroke Volume | 9 | 2026 | 655 | 1.940 |
Why?
| | Heart Failure | 11 | 2026 | 2326 | 1.920 |
Why?
| | Percutaneous Coronary Intervention | 12 | 2026 | 549 | 1.850 |
Why?
| | Rivaroxaban | 4 | 2026 | 271 | 1.850 |
Why?
| | Aspirin | 6 | 2026 | 406 | 1.800 |
Why?
| | Factor Xa Inhibitors | 3 | 2026 | 194 | 1.730 |
Why?
| | Fibrinolytic Agents | 6 | 2025 | 297 | 1.680 |
Why?
| | Lower Extremity | 5 | 2026 | 450 | 1.260 |
Why?
| | ST Elevation Myocardial Infarction | 3 | 2026 | 64 | 1.030 |
Why?
| | Spironolactone | 2 | 2026 | 40 | 1.000 |
Why?
| | Vascular Surgical Procedures | 2 | 2026 | 343 | 0.900 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2026 | 444 | 0.750 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2025 | 303 | 0.700 |
Why?
| | Thrombosis | 2 | 2024 | 400 | 0.690 |
Why?
| | Anticholesteremic Agents | 1 | 2023 | 155 | 0.680 |
Why?
| | Hyperglycemia | 1 | 2025 | 380 | 0.680 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2026 | 2602 | 0.670 |
Why?
| | Purinergic P2Y Receptor Antagonists | 8 | 2026 | 71 | 0.650 |
Why?
| | Endovascular Procedures | 1 | 2026 | 390 | 0.650 |
Why?
| | Hypertension | 6 | 2026 | 1276 | 0.640 |
Why?
| | Adenosine Monophosphate | 4 | 2026 | 85 | 0.640 |
Why?
| | Coronavirus | 1 | 2020 | 47 | 0.600 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 668 | 0.600 |
Why?
| | Venous Thrombosis | 1 | 2022 | 196 | 0.600 |
Why?
| | Blood Platelets | 3 | 2024 | 379 | 0.600 |
Why?
| | Mobile Applications | 1 | 2022 | 199 | 0.590 |
Why?
| | Hypoglycemic Agents | 3 | 2026 | 1399 | 0.590 |
Why?
| | Sex Characteristics | 2 | 2025 | 789 | 0.550 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 391 | 0.550 |
Why?
| | Coronavirus Infections | 2 | 2020 | 384 | 0.540 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2026 | 1752 | 0.520 |
Why?
| | Humans | 54 | 2026 | 145783 | 0.520 |
Why?
| | Venous Thromboembolism | 1 | 2022 | 328 | 0.520 |
Why?
| | Precision Medicine | 1 | 2021 | 461 | 0.490 |
Why?
| | Hemorrhage | 4 | 2026 | 822 | 0.480 |
Why?
| | Drug Therapy, Combination | 5 | 2026 | 1043 | 0.470 |
Why?
| | Platelet Aggregation | 4 | 2026 | 99 | 0.460 |
Why?
| | Blood Glucose | 1 | 2025 | 2344 | 0.430 |
Why?
| | Treatment Outcome | 15 | 2026 | 11794 | 0.420 |
Why?
| | Neoplasms | 4 | 2024 | 2913 | 0.420 |
Why?
| | International Classification of Diseases | 2 | 2025 | 150 | 0.410 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1101 | 0.400 |
Why?
| | Ventricular Function, Left | 5 | 2026 | 544 | 0.400 |
Why?
| | Pragmatic Clinical Trials as Topic | 2 | 2025 | 133 | 0.390 |
Why?
| | Aged | 18 | 2026 | 26217 | 0.380 |
Why?
| | Coronary Artery Disease | 4 | 2025 | 750 | 0.380 |
Why?
| | Pandemics | 2 | 2020 | 1711 | 0.360 |
Why?
| | Multicenter Studies as Topic | 2 | 2025 | 413 | 0.360 |
Why?
| | Double-Blind Method | 3 | 2026 | 2064 | 0.350 |
Why?
| | Postoperative Complications | 1 | 2024 | 2977 | 0.340 |
Why?
| | Middle Aged | 17 | 2026 | 36309 | 0.340 |
Why?
| | Aged, 80 and over | 6 | 2026 | 8347 | 0.340 |
Why?
| | Antihypertensive Agents | 2 | 2026 | 521 | 0.330 |
Why?
| | Blood Pressure | 4 | 2026 | 1782 | 0.310 |
Why?
| | Male | 24 | 2026 | 73011 | 0.300 |
Why?
| | Prevalence | 4 | 2025 | 2875 | 0.290 |
Why?
| | Anticoagulants | 4 | 2022 | 748 | 0.280 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2026 | 109 | 0.270 |
Why?
| | Female | 20 | 2026 | 79045 | 0.270 |
Why?
| | Betacoronavirus | 2 | 2020 | 289 | 0.250 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2021 | 394 | 0.250 |
Why?
| | Risk Factors | 7 | 2026 | 10919 | 0.250 |
Why?
| | Dicarboxylic Acids | 1 | 2026 | 12 | 0.240 |
Why?
| | Incretins | 1 | 2026 | 21 | 0.240 |
Why?
| | Aminobutyrates | 1 | 2026 | 31 | 0.230 |
Why?
| | Tetrazoles | 1 | 2026 | 50 | 0.230 |
Why?
| | Chagas Cardiomyopathy | 1 | 2026 | 27 | 0.230 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2026 | 41 | 0.230 |
Why?
| | Limb Salvage | 1 | 2026 | 73 | 0.230 |
Why?
| | Bumetanide | 1 | 2025 | 5 | 0.230 |
Why?
| | Adenosine | 2 | 2024 | 255 | 0.220 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2025 | 17 | 0.220 |
Why?
| | Diuretics | 1 | 2025 | 68 | 0.220 |
Why?
| | Atrial Fibrillation | 2 | 2021 | 558 | 0.220 |
Why?
| | Coronary Angiography | 4 | 2021 | 328 | 0.210 |
Why?
| | Glucagon-Like Peptides | 1 | 2026 | 71 | 0.210 |
Why?
| | Peptide Fragments | 2 | 2026 | 697 | 0.210 |
Why?
| | Hospitalization | 2 | 2025 | 2461 | 0.210 |
Why?
| | Morphine Derivatives | 1 | 2023 | 19 | 0.200 |
Why?
| | Tablets | 1 | 2023 | 41 | 0.200 |
Why?
| | Ventricular Remodeling | 1 | 2026 | 278 | 0.200 |
Why?
| | Subtilisin | 1 | 2023 | 4 | 0.200 |
Why?
| | Secondary Prevention | 1 | 2025 | 251 | 0.200 |
Why?
| | Cardiology | 2 | 2025 | 362 | 0.200 |
Why?
| | Proprotein Convertases | 1 | 2023 | 16 | 0.190 |
Why?
| | Recombinant Fusion Proteins | 1 | 2026 | 666 | 0.190 |
Why?
| | Fatty Acids | 1 | 2026 | 457 | 0.190 |
Why?
| | Proprotein Convertase 9 | 1 | 2023 | 87 | 0.190 |
Why?
| | Comorbidity | 2 | 2025 | 1662 | 0.180 |
Why?
| | Atrial Remodeling | 1 | 2022 | 10 | 0.180 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 116 | 0.180 |
Why?
| | Echocardiography | 5 | 2024 | 648 | 0.170 |
Why?
| | Bundle-Branch Block | 1 | 2021 | 37 | 0.170 |
Why?
| | Glucosephosphate Dehydrogenase Deficiency | 1 | 2021 | 34 | 0.170 |
Why?
| | Cholesterol, LDL | 1 | 2023 | 360 | 0.170 |
Why?
| | Cardiotoxicity | 1 | 2021 | 35 | 0.170 |
Why?
| | Atherosclerosis | 1 | 2025 | 409 | 0.170 |
Why?
| | Frailty | 1 | 2024 | 205 | 0.160 |
Why?
| | Drug Compounding | 1 | 2021 | 107 | 0.160 |
Why?
| | Coronary Stenosis | 1 | 2020 | 40 | 0.160 |
Why?
| | Coronary Occlusion | 1 | 2020 | 20 | 0.160 |
Why?
| | Ambulatory Care | 1 | 2025 | 610 | 0.160 |
Why?
| | Drug-Eluting Stents | 1 | 2020 | 88 | 0.160 |
Why?
| | Radial Artery | 2 | 2021 | 75 | 0.160 |
Why?
| | Myocarditis | 1 | 2021 | 102 | 0.160 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2021 | 156 | 0.150 |
Why?
| | Smoking Cessation | 1 | 2024 | 441 | 0.150 |
Why?
| | Shock, Cardiogenic | 1 | 2020 | 65 | 0.150 |
Why?
| | Angioplasty, Balloon | 1 | 2021 | 94 | 0.150 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2023 | 339 | 0.150 |
Why?
| | Italy | 3 | 2025 | 117 | 0.140 |
Why?
| | Chronic Disease | 1 | 2025 | 1812 | 0.140 |
Why?
| | Heart Arrest | 1 | 2023 | 411 | 0.140 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5925 | 0.140 |
Why?
| | Hepatitis C, Chronic | 1 | 2020 | 153 | 0.140 |
Why?
| | United States | 3 | 2025 | 16126 | 0.140 |
Why?
| | Pulmonary Embolism | 1 | 2020 | 241 | 0.140 |
Why?
| | Students, Medical | 1 | 2023 | 378 | 0.130 |
Why?
| | Time Factors | 2 | 2026 | 7134 | 0.130 |
Why?
| | Cardiomyopathies | 1 | 2021 | 335 | 0.130 |
Why?
| | Registries | 5 | 2026 | 2410 | 0.130 |
Why?
| | Biomarkers | 2 | 2025 | 4302 | 0.120 |
Why?
| | Retrospective Studies | 6 | 2025 | 17330 | 0.120 |
Why?
| | Antibodies, Monoclonal | 1 | 2023 | 1505 | 0.110 |
Why?
| | Telemedicine | 1 | 2025 | 967 | 0.110 |
Why?
| | Colorado | 1 | 2025 | 4556 | 0.110 |
Why?
| | Femoral Artery | 1 | 2016 | 190 | 0.110 |
Why?
| | Heart Ventricles | 1 | 2020 | 756 | 0.110 |
Why?
| | Cross-Over Studies | 2 | 2025 | 610 | 0.090 |
Why?
| | Cardiac Catheterization | 1 | 2016 | 559 | 0.090 |
Why?
| | Obesity | 1 | 2026 | 3118 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2219 | 0.090 |
Why?
| | Administration, Oral | 2 | 2021 | 867 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 2191 | 0.070 |
Why?
| | Prognosis | 3 | 2021 | 4330 | 0.070 |
Why?
| | Prospective Studies | 3 | 2026 | 8078 | 0.070 |
Why?
| | Valsartan | 1 | 2026 | 32 | 0.060 |
Why?
| | Biphenyl Compounds | 1 | 2026 | 67 | 0.060 |
Why?
| | Naphthyridines | 1 | 2025 | 20 | 0.060 |
Why?
| | Nasal Sprays | 1 | 2025 | 6 | 0.060 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2026 | 115 | 0.060 |
Why?
| | Administration, Intranasal | 1 | 2025 | 94 | 0.050 |
Why?
| | Receptors, Purinergic P2Y12 | 1 | 2024 | 6 | 0.050 |
Why?
| | Biological Availability | 1 | 2025 | 145 | 0.050 |
Why?
| | Platelet Function Tests | 1 | 2024 | 35 | 0.050 |
Why?
| | Drug Combinations | 1 | 2026 | 396 | 0.050 |
Why?
| | Hypolipidemic Agents | 1 | 2025 | 89 | 0.050 |
Why?
| | Adult | 3 | 2022 | 40881 | 0.050 |
Why?
| | Risk Assessment | 2 | 2025 | 3752 | 0.050 |
Why?
| | Recurrence | 1 | 2026 | 1139 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2024 | 782 | 0.050 |
Why?
| | Prasugrel Hydrochloride | 1 | 2022 | 22 | 0.040 |
Why?
| | Equivalence Trials as Topic | 1 | 2022 | 35 | 0.040 |
Why?
| | Emergencies | 1 | 2023 | 174 | 0.040 |
Why?
| | Gadolinium | 1 | 2021 | 84 | 0.040 |
Why?
| | Vitamin K | 1 | 2021 | 46 | 0.040 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2021 | 70 | 0.040 |
Why?
| | Heart Atria | 1 | 2022 | 141 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2025 | 475 | 0.040 |
Why?
| | Disease Management | 1 | 2024 | 653 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2110 | 0.040 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2020 | 124 | 0.040 |
Why?
| | Hepacivirus | 1 | 2020 | 242 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2020 | 246 | 0.040 |
Why?
| | Contrast Media | 1 | 2021 | 497 | 0.030 |
Why?
| | Acute Disease | 1 | 2021 | 1036 | 0.030 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2020 | 248 | 0.030 |
Why?
| | Age Factors | 1 | 2024 | 3346 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 2028 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 2123 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 2139 | 0.030 |
Why?
| | Stents | 1 | 2020 | 564 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2933 | 0.020 |
Why?
| | Incidence | 1 | 2020 | 2934 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 644 | 0.020 |
Why?
| | Body Mass Index | 1 | 2022 | 2447 | 0.020 |
Why?
| | Quality of Life | 1 | 2025 | 3211 | 0.020 |
Why?
| | Patient Safety | 1 | 2016 | 356 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 6033 | 0.020 |
Why?
| | Length of Stay | 1 | 2016 | 1350 | 0.020 |
Why?
| | Hypertension, Pulmonary | 1 | 2020 | 1957 | 0.020 |
Why?
| | Animals | 1 | 2021 | 38102 | 0.010 |
Why?
|
|
Canonico's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|